Literature DB >> 18299410

Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury.

John F Mohr1, Luis Ostrosky-Zeichner, David J Wainright, Donald H Parks, Timothy C Hollenbeck, Charles D Ericsson.   

Abstract

Daptomycin pharmacokinetics were evaluated for burn patients. Burn patients had decreases in the maximum concentration of the drug in serum (44%) and the area under the concentration-time curve (47%) and increases in the volume of distribution (64%) and total clearance (77%) compared to healthy volunteers. In burn patients, daptomycin at 10 to 12 mg/kg of body weight/day would be required to achieve drug exposures similar to those for healthy volunteers receiving 6 mg/kg.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18299410      PMCID： PMC2346633          DOI： 10.1128/AAC.01321-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Population pharmacokinetics of ceftazidime in burn patients.

Authors:  Eric Dailly; Michel Pannier; Pascale Jolliet; Michel Bourin
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Protein loss across burn wounds.

Authors:  K Waxman; T Rebello; L Pinderski; K O'Neal; N Khan; S Tourangeau; E Himes; K Cordill
Journal:  J Trauma       Date:  1987-02

3.  Pharmacokinetics of cefepime in patients with thermal burn injury.

Authors:  C R Bonapace; R L White; L V Friedrich; E D Norcross; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.

Authors:  P Bourget; A Lesne-Hulin; R Le Reveillé; H Le Bever; H Carsin
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 5.  Daptomycin - a novel antibiotic against Gram-positive pathogens.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Expert Opin Pharmacother       Date:  2004-11       Impact factor: 3.889

6.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

7.  Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Prachi K Dandekar; Pamela R Tessier; Peter Williams; Charlie H Nightingale; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

Review 8.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

9.  Imipenem pharmacokinetics in patients with burns.

Authors:  B A Boucher; W L Hickerson; D A Kuhl; A M Bombassaro; G S Jaresko
Journal:  Clin Pharmacol Ther       Date:  1990-08       Impact factor: 6.875

10.  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

Authors:  Barry H Dvorchik; David Brazier; Michael F DeBruin; Robert D Arbeit
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  13 in total

Review 1.  [Antimicrobial treatment in burn injury patients].

Authors:  T Trupkovic; J Gille; H Fischer; S Kleinschmidt
Journal:  Anaesthesist       Date:  2012-03       Impact factor: 1.041

Review 2.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

3.  Comparison of the pharmacokinetics of linezolid in burn and non-burn rabbits.

Authors:  Jian-Li Ma; Lei Gao; Xiang Li; Wan-Li Chu; Yong-Qiang Feng; Xiao-Qin Wang; Qing-Zhe Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-13       Impact factor: 2.441

Review 4.  The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Authors:  Marta Ulldemolins; Jason A Roberts; Jordi Rello; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

5.  In Vitro-In Vivo Correlation for the Antibacterial Effect of Lactiplantibacillus plantarum as a Topical Healer for Infected Burn Wound.

Authors:  Fatemeh Moraffah; Melika Kiani; Mohammad Abdollahi; Sepideh Yoosefi; Alireza Vatanara; Nasrin Samadi
Journal:  Probiotics Antimicrob Proteins       Date:  2022-03-29       Impact factor: 4.609

6.  The clinical relevance of plasma protein binding changes.

Authors:  Jason A Roberts; Federico Pea; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

7.  Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury.

Authors:  Andrew J Dalley; Renae Deans; Jeffrey Lipman; Bala Venkatesh; Michael Rudd; Michael S Roberts; Sheree E Cross
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

8.  [Not Available].

Authors:  R Le Floch; E Naux; J F Arnould
Journal:  Ann Burns Fire Disasters       Date:  2015-06-30

Review 9.  High-Dose Daptomycin and Clinical Applications.

Authors:  Timothy W Jones; Ah Hyun Jun; Jessica L Michal; William J Olney
Journal:  Ann Pharmacother       Date:  2021-02-04       Impact factor: 3.154

10.  Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.

Authors:  Beth White; R Andrew Seaton
Journal:  Infect Drug Resist       Date:  2011-05-24       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.